Patent · US Active

Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate

US11141413B2 · kind B2 · utility

3Cited by

22References

21Claims

0Family size

Assignee

Exelixis, Inc. · US

Inventors

Dana T. Aftab · San Rafael, US
Gisela Schwab · Hayward, US
Colin Hessel · Redwood City, US
Christian Scheffold · Palo Alto, US
Steven Lacy · San Mateo, US
Dale Miles · Sunnyvale, US
Alan Arroyo · Danville, US
Mark Dean · Te Puke, NZ

Key dates

Filing date	Apr 17, 2017
Grant date	Oct 12, 2021
Priority date	—
Expiry date	Apr 17, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.